Catalogue Number
AV-H26065
Analysis Method
HPLC,NMR,MS
Specification
98%
Storage
2-8°C
Molecular Weight
316.26
Appearance
Powder
Botanical Source
Artemisia argyi Levl.et Vant.; Artemisia austriaca Jacq/" Isol. from Eupatorium cuneifolium, Artemisia tridentata, Digitalis spp., Lippia nodiflora and many other plants"
Structure Type
Flavonoids
Category
Standards;Natural Pytochemical;API
SMILES
COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O
Synonyms
5,7,3',4'-Tetrahydroxy-6-methoxyflavone/Flavone, 3',4',5,7-tetrahydroxy-6-methoxy-/Nepetin/4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-/2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one/3',4',5,7-Tetrahydroxy-6-methoxyflavone/6-METHOXYLUTEOLIN/Eupafolin/2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one
IUPAC Name
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one
Density
1.6±0.1 g/cm3
Solubility
Methanol; DMF
Flash Point
250.9±25.0 °C
Boiling Point
659.1±55.0 °C at 760 mmHg
Melting Point
267ºC
InChl
InChI=1S/C16H12O7/c1-22-16-11(20)6-13-14(15(16)21)10(19)5-12(23-13)7-2-3-8(17)9(18)4-7/h2-6,17-18,20-21H,1H3
InChl Key
FHHSEFRSDKWJKJ-UHFFFAOYSA-N
WGK Germany
RID/ADR
HS Code Reference
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:520-11-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
24289155
Background & aim
Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic hepatitis B (CHB) patients.
Methods
Liquid chromatography combined with tandem mass spectrometry (LC-MS/MS) was used to identify differentially expressed peptides in sera from 40 CHB patients (20 with S0G0-S1G1 and 20 with S3G3-S4G4). Ion pair quantification from differentially expressed peptides in a validation set of sera from 86 CHB patients was done with multiple reaction monitoring (MRM).
Results
21 differentially represented peptide peaks were found through LC-MS/MS. Ion pairs generated from eleven of these peptides (m/z < 800) were quantified by MRM. Summed peak area ratios of 6 ion pairs from peptide m/z 520.3 (176.1, 353.7, 459.8, 503.3, 351.3, 593.1), which was identified as dihydroxyacetone kinase (DAK) fragment, decreased from mild to advanced stages of fibrosis or inflammation. Area Under Receiver Operating Characteristic Curves (AUROCs) of five ion models discriminating fibrosis degrees were 0.871 ~ 0.915 (S2-4 versus S0-1) and 0.804 ~ 0.924 (S3-4 versus S0-2). AUROCs discriminating inflammation grades were 0.840 ~ 0.902 (G2-4 versus G0-1) and 0.787 ~ 0.888 (G3-4 versus G0-2). The diagnostic power of these models provides improved sensitivity and specificity for predicting disease progression as compared to aspartate aminotransferase to platelet ratio index (APRI), FIB-4, Forn’s index and serum DAK protein.
Conclusions
The peptide fragment (m/z 520.3) of DAK is a promising biomarker to guide timing of antiviral treatment and to avoid liver biopsy in compensated CHB patients.
Peptidome, Dihydroxyacetone kinase, Chronic hepatitis B, Multiple reaction monitoring, Liquid chromatography combined with tandem mass spectrometry
Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B
Ming-Yi Xu,#1 Xiao-Fang Jia,#2 Ying Qu,1 Rui-Dan Zheng,3 Zheng-Hong Yuan,2 Hong-Lei Weng,4 Steven Dooley,4 Xing-Peng Wang,1 Li-Jun Zhang,corresponding author2 and Lun-Gen Lucorresponding author1
2013;
30029854
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules.
ebolavirus, monoclonal antibodies, viral antibodies, neutralizing antibodies, cross protection, heterologous immunity, glycoproteins, Ebola hemorrhagic fever, epitopes, epitope mapping
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
Pavlo Gilchuk,1 Natalia Kuzmina,6,7 Philipp A. Ilinykh,6,7 Kai Huang,6,7 Bronwyn M. Gunn,9 Aubrey Bryan,10 Edgar Davidson,10 Benjamin J. Doranz,10 Hannah L. Turner,11 Marnie L. Fusco,13 Matthew S. Bramble,14,15 Nicole A. Hoff,14 Elad Binshtein,4 Nurgun Kose,1 Andrew I. Flyak,2 Robin Flinko,16 Chiara Orlandi,16 Robert Carnahan,1 Erica H. Parrish,1 Alexander M. Sevy,3 Robin G. Bombardi,1 Prashant K. Singh,4 Patrick Mukadi,17 Jean Jacques Muyembe-Tamfum,17 Melanie D. Ohi,4,18 Erica Ollmann Saphire,11,12,13 George K. Lewis,16 Galit Alter,9 Andrew B. Ward,11 Anne W. Rimoin,14 Alexander Bukreyev,6,7,8,18,? and James E. Crowe, Jr.1,2,3,5,18,19,??
2018 Aug 21;
24960209
We have developed a series of dihydroxy compounds and related analogues based on our hybrid D2/D3 agonist molecular template to develop multifunctional drugs for symptomatic and neuroprotective treatment for Parkinson’s disease (PD). The lead compound (?)-24b (D-520) exhibited high agonist potency at D2/D3 receptors and produced efficacious activity in the animal models for PD. The data from thioflavin T (ThT) assay and from transmission electron microscopy (TEM) analysis demonstrate that D-520 is able to modulate aggregation of alpha-synuclein (αSN). Additionally, coincubation of D-520 with αSN is able to reduce toxicity of preformed aggregates of αSN compared to control αSN alone. Finally, in a neuroprotection study with dopaminergic MN9D cells, D-520 clearly demonstrated the effect of neuroprotection from toxicity of 6-hydroxydopamine. Thus, compound D-520 possesses properties characteristic of multifunctionality conducive to symptomatic and neuroprotective treatment of PD.
Parkinson’s disease, D2/D3 agonist, alpha-synuclein, neuroprotection, multifunctional drug
Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates
Gyan Modi,† Chandrashekhar Voshavar,† Sanjib Gogoi,† Mrudang Shah,† Tamara Antonio,‡ Maarten E. A. Reith,‡§ and Aloke K. Duttacorresponding author†*
2014 Aug 20
Description :
Empty ...